Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Heat Biologics Inc (HTBX)

Heat Biologics Inc (HTBX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
NightHawk Biosciences Provides First Quarter 2022 Business Update Globe Newswire - Mon May 16, 2022

DURHAM, N.C., May 16, 2022 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK), a fully integrated biopharmaceutical company focused on...

HTBX : 2.38 (+0.42%)
NHWK : 0.4135 (+8.96%)
Heat Biologics Completes Name Change to NightHawk Biosciences; Trading to Commence Under “NHWK” Effective at the Market Open Today Globe Newswire - Tue May 3, 2022

DURHAM, N.C., May 03, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. / NightHawk Biosciences (NYSE American: HTBX; NHWK), a fully integrated...

HTBX : 2.38 (+0.42%)
Heat Biologics (“NightHawk Biosciences”) Completes Acquisition of Elusys Therapeutics Globe Newswire - Wed Apr 20, 2022

Elusys becomes wholly-owned biodefense subsidiary of NightHawk Plans to expand ANTHIM® distribution abroad DURHAM, N.C., April 20, 2022 (GLOBE...

HTBX : 2.38 (+0.42%)
Heat Biologics Announces Planned Name Change to NightHawk Biosciences, Reflecting Company’s Evolution, Therapeutic Pipeline Expansion, Vertical Integration and New Biodefense Capabilities Globe Newswire - Tue Apr 19, 2022

Key Corporate Updates Announced Via Livestream Event from Manhattan, Kansas, available for replay at Nighthawkbio.com...

HTBX : 2.38 (+0.42%)
Heat Biologics’ Scorpion Subsidiary Announces Planned Development of New Kansas Commercial/Biodefense Biomanufacturing Facility Globe Newswire - Mon Apr 18, 2022

500,000+ square foot facility to support commercial-scale biomanufacturing Livestreaming ceremony with Governor Laura Kelly Live from Manhattan, Kansas...

HTBX : 2.38 (+0.42%)
Heat Biologics’ Announces Planned Investor and Media Livestream Event to Discuss Latest Developments Globe Newswire - Thu Apr 14, 2022

DURHAM, N.C., April 14, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NYSE American: HTBX), a clinical-stage biopharmaceutical company focused...

HTBX : 2.38 (+0.42%)
Heat Biologics Unveils Enhanced Allogeneic Cell Manufacturing Process Globe Newswire - Fri Mar 25, 2022

New 3-D process designed to increase yield and improve operating efficiency for rapid and scalable manufacturing of HS-110, gp-96 based cell therapies and...

HTBX : 2.38 (+0.42%)
Heat Biologics Announces Appointment of Greg Burel, Former Director of the Strategic National Stockpile, to its Biothreat Advisory Board and as Senior Advisor to the Company Globe Newswire - Wed Mar 23, 2022

Burel to support anthrax and RapidVax™ biodefense initiatives as a platform for rapid response to known and unknown biological threats...

HTBX : 2.38 (+0.42%)
Heat Biologics Announces Planned Transfer to the NYSE American Globe Newswire - Wed Feb 2, 2022

DURHAM, N.C., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on...

HTBX : 2.38 (+0.42%)
Elusys Therapeutics Finalizes HHS Contract to Deliver ANTHIM®, Its Treatment for Inhalation Anthrax, to the U.S. Department of Health and Human Services Globe Newswire - Mon Jan 31, 2022

Completed first phase of contract for $50 million; HHS options to procure up to $31 million of ANTHIM by the first half of 2023 Reaffirms ANTHIM as an...

HTBX : 2.38 (+0.42%)

Barchart Exclusives

3 Energy Dividend Stocks to Invest in Oil's 'Higher for Longer' Scenario Barchart - Thu May 2, 6:30PM CDT
Discover how Schlumberger, Baker Hughes, and Halliburton are leveraging their robust financial health and strategic initiatives to thrive in a market where oil prices are expected to remain elevated, in our latest deep dive into the energy sector's top performers. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot